We believe omadacycline will be used in the emergency room, hospital, and community settings. We have designed omadacycline to provide significant advantages over existing antibiotics, including activity against resistant bacteria, broad spectrum of coverage, intravenous, or IV, and oral formulations with once-daily dosing, and a favorable safety and tolerability profile. We believe that it will become the primary antibiotic choice of physicians for use as a first-line monotherapy for acute bacterial skin and skin structure infections, or ABSSSI, community-acquired bacterial pneumonia, or CABP, urinary tract infections, or UTI, and other serious community-acquired bacterial infections.
Our second most advanced product candidate, WC 3035, is a novel tetracycline-derived compound designed for use in the treatment of acne and rosacea. WC 3035 has demonstrated favorable anti-inflammatory activity, narrow-spectrum antibacterial activity relative to other tetracycline-derived molecules, oral bioavailability, and favorable pharmacokinetic, or PK, properties which we believe make it particularly well-suited for the treatment of acne and rosacea in the community setting. We have licensed rights to WC 3035 for the treatment of acne and rosacea in the United States to a subsidiary of Actavis (formerly Warner Chilcott), while retaining rights in the rest of the world. Actavis is responsible for the clinical development of WC 3035 for the treatment of acne in the United States, following a successful phase 2 clinical trial; a phase 3 clinical trial is planned for the second half of 2014 of this product candidate for this indication.
In addition to omadacycline and WC 3035, we have advanced a series of product candidates through to proof of concept in animal models. We designed these next generation, tetracycline-derived, new molecular entities using our proprietary drug development platform, and incorporated the recognized immune-modulation, anti-inflammatory, and other properties of the tetracycline class. We believe that, based on our preclinical testing to date, the potential for these small molecule therapies to treat debilitating neurological and inflammatory diseases such as multiple sclerosis, spinal muscular atrophy, rheumatoid arthritis, and inflammatory bowel disease, is promising. In addition, we have an early-stage program focused on the treatment of Clostridium difficile associated diarrhea, as well as a program focused on important animal health diseases.
Michael F. Bigham, MBA
Chairman of the Board and Chief Executive Officer
The Paratek team enjoys a broad range of management experience developed across the biotechnology and pharmaceutical sectors.
Michael F. Bigham, MBA, was appointed Chief Executive Officer and Chairman of the Board of Directors in June 2014. Mr. Bigham is a Partner at Abingworth LLP, a leading international investment group dedicated to life sciences and healthcare, and has more than 25 years of senior leadership experience in the biopharmaceutical industry. He currently serves on the boards of Avedro and Secure EDI and has held several directorships including Avila Therapeutics where he was the founding Chairman and CEO, Magellan Biosciences, Portola Pharmaceuticals, Supernus Pharmaceuticals and Valeritas. Michael was formerly Vice Chairman of Corixa Corporation, a publicly-traded biotechnology company, and was President and Chief Executive of Coulter Pharmaceuticals, a publicly-traded oncology company, until it merged into Corixa. Previously, he was an early employee at Gilead Sciences where he served in various capacities, including Executive Vice President of Operations and Chief Financial Officer. Before joining Gilead, Mr. Bigham was a Partner at Hambrecht & Quist where he became Co-Head of Healthcare Investment Banking. Michael qualified as a CPA before completing his MBA at Stanford University.
Evan Loh, MD, was appointed President in June 2014, serves as our Chief Medical Officer, and also serves on our board of Directors. From October 2009 to January 2012, Dr. Loh served as Senior Vice President, Development and Strategic Operations, Worldwide Research and Development, at Pfizer. While at Pfizer, Dr. Loh’s responsibilities included scientific, operational, and strategic drug development oversight for all pre-proof of concept development phase programs and leading portfolio prioritization. Prior to joining Pfizer, from January 2007 to October 2009, Dr. Loh was Vice President, Clinical Research & Development at Wyeth, where he was responsible for leadership and strategic oversight of clinical development efforts across multiple therapeutic areas throughout the world. He is the 2006 recipient of the Heroes of Chemistry Award from the American Chemical Society for his leadership role at Wyeth in the clinical development of Tygacil. Dr. Loh served as a faculty member at both Harvard Medical School and the University of Pennsylvania School of Medicine. Dr. Loh received his A.B. from Harvard College and his M.D. from Harvard Medical School. He completed his Internal Medicine and Cardiovascular fellowship training at Brigham and Women’s Hospital.
Richard Lim, MBA, joined our board of directors in March of 2014. Mr. Lim is a Partner at Omega Funds and has over 20 years in principal investment and strategic consulting, all within life science and healthcare. He was previously a General Partner at MVM Life Science Partners, a life science focused venture capital firm with $500 million under management; he founded MVM’s US investment operations. He was previously a Vice President at Saunders, Karp & Megrue (SKM), a private equity firm with $1.7bn under management, where he specialized in healthcare growth capital and leveraged transactions. Prior to SKM (now known as Apax Partners Inc.), Richard was a Manager at LEK Consulting, providing strategic advice to life science companies; he consulted for more than 3 dozen small and large biotechnology firms. He was also an Associate with M&A investment bank BT Wolfensohn. He has served on a number of boards in biotechnology, specialty pharmaceuticals, and medical device companies. He serves as a catalyst advisor of the Deshpande Center at the Massachusetts Institute of Technology. He earned AB and MBA degrees from Harvard University.
|Jul 01, 2014||Transcept and Paratek Pharmaceuticals Sign Merger Agreement; $111 Million of Capital Investments Committed|
|Jul 01, 2014||Paratek Appoints Michael Bigham as Chairman and CEO and Promotes Evan Loh to President and CMO|
|May 01, 2013||Paratek Pharmaceuticals Announces Expanded FDA Grant of Qualified Infectious Disease Product (QIDP) Designation for Its Lead Product Candidate, Omadacycline|
|Jan 03, 2013||Paratek Pharmaceuticals Announces FDA Grant of Qualified Infectious Disease Product (QIDP) Designation for its Lead Product Candidate, Omadacycline|
|Mar 28, 2012||Paratek Wins Agreement with FDA on Special Protocol Assessment (SPA) for Phase 3 Study in Community-Acquired Bacterial Pneumonia|
|Sep 10, 2010||Paratek to Present Clinical Data at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy|
To contact Paratek investor relations, please email us at email@example.com.
Poster Presented at 52nd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), September 9-12, 2012
Posters Presented at 22nd European Congress on Clinical Microbiology and Infectious Diseases (ECCMID), March 30-April 3, 2011
Antimicrobial Activity of PTK 0796 (Omadacycline) and Comparator Agents Against Contemporary Pathogens Commonly Associated with Community-Acquired Respiratory Tract Infections Collected During 2011 from the European Union
Poster Presented at 51st Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), September 17-20, 2011
Posters Presented at 21st European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) / 27th International Congress of Chemotheraphy (ICC), May 7-10, 2011
In a phase 2 complicated skin and soft tissue infections trial, outcomes assessed early in the course of therapy were consistent with outcomes 10-17 days after completing therapy with either omadacycline (OMC; PTK796) or linezolid, Poster P1528
Posters Presented at 50th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), September 12-15, 2010
Poster Presented at Annual European League Against Rheumatism (EULAR) Congress, June 10-13, 2009
Posters Presented at 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), October 25-28, 2008
Poster Presented at 15th International Inflammation Research Association Conference, September 21-24, 2008
Poster Presented at 60th Annual Meeting of the American Academy of Neurology, April 12-19, 2008
Poster Presented at 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), September 18, 2007
Poster Presented at 107th General Meeting of the American Society for Microbiology (ASM), May 22, 2007
Posters Presented at 46th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), September 30, 2006
Posters Presented at 43rd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), September 15, 2003
Paratek Pharmaceuticals, Inc.
75 Kneeland Street
We are looking for highly motivated, bright, and committed individuals to join our team. If you would like to be considered for positions at Paratek, please submit your resume by email to: firstname.lastname@example.org.
Paratek Pharmaceuticals, Inc. is an Equal Opportunity Employer.
Via MBTA: Take Red Line to South Station. Go left onto Atlantic Avenue. Go right onto Kneeland Street. Enter 75 Kneeland Street; take the elevator to the 6th floor. We are through the door on the left.
From Mass Turnpike East: Follow turnpike East to exit 24a/SouthStation, and go left onto Kneeland Street off the exit ramp. Enter 75 Kneeland Street and take the elevator to the 6th floor. We are through the door on the left. (Parking instructions are given below.)
From 93 North: Take exit 20, follow signs for South Station. Make a left at the fourth stop light onto Kneeland Street. Enter 75 Kneeland Street; take the elevator to the 6th floor. We are through the door on the left. (Parking instructions are given below.)
From 93 South: Take exit 23/Purchase Street, as you come out of the tunnel follow roadway as it winds through construction and becomes Purchase St. Continue through financial district on Purchase street across Congress, Summer and Lincoln Streets. Continue along Purchase Street as you approach Chinatown the road becomes Surface Artery, continue until the light at Kneeland Street and make a left onto Kneeland. Enter 75 Kneeland Street; take the elevator to the 6th floor. We are through the door on the left. (Parking instructions are given below.)
Parking (on Tyler): From Kneeland Street, go to Tyler Street. Make a right and park on the left at the open-air parking lot.
Parking (at New England Medical Center): Continue on Kneeland to Washington Street. Make a left and follow signs for Parking.